GZGuangsheng Zhao

Guangsheng Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guangsheng Zhao has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Guangji Yu

    Department of Interventional Therapy, Linyi Cancer Hospital, Linyi, Shandong Province, China

    1 shared publication
  • Guangsheng Zhao

    Hepatobiliary and Pancreatic Center, Beijing Tsinghua Changgeng Hospital, Changping District, Beijing; Department of Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning Province, China

    1 shared publication
  • Nannan Guo

    Department of Oncology, Binzhou People's Hospital, Binzhou, Shandong Province, China

    1 shared publication
  • Song Liu

    Department of Interventional Therapy, Linyi Cancer Hospital, Linyi; Affiliated provincial hospital, Shandong University School of Clinical Medicine, Jinan, Shandong Province, China

    1 shared publication
  • Song Liu

    Dalian Medical University, Dalian, Liaoning 116044, P.R. China

    1 shared publication
  • Ying Liu

    Department of Interventional Radiology Affiliated Zhongshan Hospital of Dalian University Dalian P.R. China

    1 shared publication

Latest Publications

  • Transcatheter arterial chemoembolization combined with low-dose apatinib in the treatment of unresectable hepatocellular carcinoma in elderly patients: Efficacy and safety

    by Qiang Li, Zhe Wang, Song Liu, Guangsheng Zhao, Guangji Yu, Nannan Guo, Yuewei Zhang

    Context: Owing to the increasing age of the population, the incidence of hepatocellular carcinoma (HCC) in the elderly is increasing annually. Aims: This study aims to investigate the clinical efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with low-dose apatinib for unresectable HCC treatment in elderly patients (≥65 years). Settings and Design: The clinical data from 61 elderly patients with unresectable HCC who were retrospectively analyzed. Subjects and Methods: Of these 61 patients, 27 received TACE combined with low-dose (250 mg/qd) apatinib (experimental group), and 34 patients received the standard TACE treatment (control group). The short-term efficacy was evaluated according to the mRECIST1.1 standards, and the mid- and long-term efficacy and safety in the two groups of patients were evaluated. Statistical Analysis Used: Statistical analyses were performed using the Statistical Package for the Social Sciences software (version 20.0; SPSS). Results: Both the objective response rate and disease control rate of the experimental group were significantly higher than those of control group (P < 0.05). The 6-month and 12-month survival rates of the experimental group were significantly higher than those of control group too (P < 0.05). The median survival in the experimental group was longer than in the control group (26.0 months vs. 20.0 months). The adverse reactions related to the intake of apatinib were higher in the experimental than the control group, but were generally alleviated after symptomatic treatment. Conclusions: TACE combined with low-dose apatinib provides an alternative treatment option for elderly patients with unresectable HCC. Our clinical study has proven its safety and efficacy.


  • Open Access

    Complete remission of diffuse hepatocellular carcinoma in a young adult after GSP-TACE: a case report

    by Song Liu, Yuewei Zhang, Guangsheng Zhao, Ying Liu

    Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver. It mostly occurs in older age groups (usually those 50 to 60 years old), and rarely in young adults. The survival rate of these young HCC patients is usually very low. The authors report a case of a 22-year old man with diffuse-type HCC who successfully achieved complete remission for 46 months after second transcatheter arterial chemoembolization using gelatin sponge particles (Eric Kang Pharmaceutical Technology Co., Ltd. Hangzhou, China) combined with pirarubicin.